| Prev Close | 298.20 |
| Open | 299.19 |
| Day Low/High | 295.78 / 299.69 |
| 52 Wk Low/High | 287.66 / 442.00 |
| Volume | 492.34K |
| Avg Volume | 898.20K |
Regeneron Pharmaceuticals Inc. (REGN)
298.37
0.17
0.06
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 107.73M |
| Market Cap | 32.08B |
| EPS | 22.60 |
| P/E Ratio | 13.85 |
| Div & Yield | N.A. (N.A) |
Cramer: Biogen's Horseman May Have Fallen Off, I Like Others More
TheStreet's Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.
When Leader Goes Down, Whole Sector Feels It
Biogen's weak numbers leave biotechs ailing.
Are Any New FANGs Baring Their Teeth?
The fearsome foursome have been reborn.
Cramer: Own Starbucks Over Dunkin, PayPal IPO Is a Buy Right Now
Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.
iShares Nasdaq Biotech ETF is Just What the Doctor Ordered for Your Portfolio
Technical factors point to a looming breakout for IBB.
Regeneron Reaches a Great Entry Point
This could be an opportune price to buy REGN, as it allows you to take a position fairly close to well-defined support.
Biotech Moves Are Anything But Crazy
New companies are coming up with major drugs.
A Stellar Day. But Why?
Bulls have the upper hand again.
Playing Biotechs with the House's Money
Here's how to lock in gains on risky small-cap biotechnology stocks.
Cramer: Intel Had to Be Aggressive With Altera, Don't Sell Amgen
Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.
What's Wrong With Betting on One Stock?
'Single-stock risk' is all the rage these days.
Why I'm Looking at Biotechs, Not Airlines
Cutthroat competition is good for customers, but not shareholders.
3 Biotechs That Are Worth Buying
Many of these stocks are off to the races.
The Second-Strongest Stock Market Sector Doesn't Jibe With the Strongest
You could throw darts at financials and health care and win.
Where to Invest to Shelter From the Market Rotation Crossfire
Some companies are so strong that they buck the rotation.
Cramer: I Like Receptos and Radius, as Well as the Four Horsemen
Jim Cramer answers viewers' stock questions from the floor of the New York Stock Exchange.
Janet Yellen, Stock Market Commentator?
It's not the Fed chief's place.
Here's What's Driving Biotech
And it's not the favorable macroeconomic climate.
I'm Going to Keep Riding These Horses
Biogen miss no reason to abandon big 4 of Big Pharma.
Mylan Deal the Rx for Drug Stocks
Even the second-tier biotechs are taking off.
Biotech Investors: Buy In or Get Out
No more hand-holding on these names.
Portfolio Managers Shop for Growth
Combined Heinz-Kraft heads a long second-quarter list.
Answering Your Tweets
An answer to those asking me what's worth buying.
Biotech, Chips Stand Their Ground
You can't help but feel better about both groups.
Biotechs Need to Rest
If there is no catalyst, I'd join those who sell on a bounce.
Backing Away From Biotechs
This sector could see some real damage.
The 7 Pillars of Healthcare Strength
Here are healthcare stocks of all shares and sizes with strong charts.
Biotech Stocks at a Crossroad
Own them, or take something off the table?
I'm Making a Don't-Buy Call on Biotech
I really like the stocks. But I also like making money on stocks.
